429 |
Achieving the Superior Treatment Goal for Patients at Risks Through Powerful Inhibition of Two Sources of Cholesterol -"VYTAL Study" |
Szilard Voros |
Nov. 09. 07 |
428 |
Optimizing the Treatment for Hypertensive Patients Led by Evidence: Is It All about Blood Pressure? |
Jeong Bae Park |
Nov. 09. 07 |
427 |
Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering |
Matthew Worthley |
Nov. 09. 07 |
426 |
Effects of Statin Therapy on Ruptured Coronay Plaque |
Myeong-Ki Hong |
Nov. 09. 07 |
425 |
Stem Cell Therapy for Ischemic Heart Disease - What Do We Know from Clinical Trials? |
Birgit Assmus |
Nov. 09. 07 |
424 |
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High Risk PCI |
Charles A. Simonton |
Nov. 02. 07 |
423 |
Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible |
Gregg W. Stone |
Nov. 02. 07 |
422 |
Pushing the Envelope for Bivalirudin Monotherapy: Design, Rationale, and Status of ISARREACT-4 and HORIZONS |
Adnan Kastrati |
Nov. 02. 07 |
421 |
ISAR-CHOICE-2: Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI |
Adnan Kastrati |
Nov. 02. 07 |
420 |
Dual Antiplatelet Therapy: How Long Should It Be Continued after DES Implantation? |
Cheol Whan Lee |
Nov. 02. 07 |